Prescription Drug User Fee Act (PDUFA) Reauthorization

FDA and Industry Finance Subgroup | Minutes

November 18th, 2020 | 9:00am-12:00pm

Virtual Format (Zoom)

PARTICIPANTS

FDA          Industry
Josh Barton   E. Cartier Esham   BIO
Yanming Chae  Carl Garner       PhRMA (Eli Lilly)
Angela Granum Brad Glasscock   BIO (BioMarin)
Bharat Khanna Kelly Goldberg   PhRMA
Ted Liazos    Ann Kurowski      BIO (Alkermes)
Alison Lyndaker Kristy Lupejkis PhRMA
Robert Marcarelli Mark Taisey   PhRMA (Amgen)

Lucy Vereshchagina PhRMA

MEETING SUMMARY

Limited Allowable Expenditures Under FDARA Section 905(b)
FDA and Industry discussed the limitation of allowable expenses that under current law will take effect on October 1st, 2023. After the FDA highlighted the anticipated adverse impacts of this section on the program, FDA and Industry discussed if this can be addressed through the PDUFA reauthorization process.

Inflation Adjustment
FDA and Industry continued discussion on FDA’s inflation adjustment proposal, which is to update the Personnel Costs and Benefits (PC&B) component of the inflation adjustment to represent actual changes in PDUFA-program specific PC&B rather than actual changes in total FDA PC&B. FDA presented on the current mechanisms of the inflation adjustment and provided analysis on the projected impact on fee amounts. FDA noted that this change would support its ability to fund PC&B for existing PDUFA program staffing and is necessary to ensure that FDA can fund pay flexibilities and strategies for staff retention over the long-term. This proposal will be discussed further at a subsequent meeting.

Resource Capacity Planning Follow-Up
FDA and Industry continued the discussion of the FDA proposal on continuous enhancement of the Resource Capacity Planning capabilities in the PDUFA program. FDA addressed Industry clarifying questions on the use of Resource Capacity Planning. This proposal will be discussed further at a subsequent meeting.

There were no other substantive proposals, significant controversies, or differences of opinion discussed at this meeting.